What Causes Hemoptysis?
Discussion
True hemoptysis is a very uncommon or rare problem in pediatrics but can be potentially life-threatening. Massive hemoptysis has a high mortality (up to 50%) mainly from asphyxia and inability to ventilate and oxygenate the patient because of blood in the pulmonary airways. Fortunately, most hemoptysis is small in amount that resolves within 24 hours.
Initial evaluation for hemoptysis can include complete blood count, coagulation studies, C-reactive protein, erythrocyte sedimentation rate, urinalysis (possible pulmonary-renal problems), radiographic imaging including chest x-ray and/or computed tomography, and...
Source: PediatricEducation.org - April 22, 2024 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
S2 Episode 5: Pulmonary Hypertension: Essential Insights for Cardiologists S2 Episode 5: Pulmonary Hypertension: Essential Insights for Cardiologists
Drs Michelle Kittleson and Ronald Oudiz dive into everything cardiologists need to know about the diagnosis and treatment of pulmonary hypertension.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 18, 2024 Category: Consumer Health News Tags: Cardiology InDiscussion Source Type: news
MT Improves Outcomes for Pulmonary Hypertension MT Improves Outcomes for Pulmonary Hypertension
The use of mechanical thrombectomy was associated with short- and long-term improvements in pulmonary hypertension in adults with pulmonary embolism.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 1, 2024 Category: Consumer Health News Tags: Pulmonary Medicine Source Type: news
Acute high-output heart failure with pulmonary hypertension and severe liver injury caused by amlodipine poisoning: a case report - Wang C, Zhu Q, Tan D, Walline J, Wang Y.
We report a 52-year-old woman who suffered from severe shock after an overdose of amlodipine. Hemodynamic monitoring showed tha... (Source: SafetyLit)
Source: SafetyLit - March 28, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Aria CV announces first patient implant of device to treat pulmonary hypertension
A St. Paul-based med-tech company celebrated Valentine's Day with the first implant of its second-generation heart implant device to treat pulmonary hypertension. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 27, 2024 Category: Pharmaceuticals Authors: Cam Bonelli Source Type: news
PHA's Weekend in Houston Spreads Pulmonary Hypertension Awareness April 6-7
The Pulmonary Hypertension Association will be in Houston, April 6-7, hosting a weekend of events dedicated to raising pulmonary hypertension awareness and supporting the PH community in and around the Greater Houston area. WASHINGTON, Feb. 22, 2024 /PRNewswire-PRWeb/ -- The Pulmonary... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 22, 2024 Category: Pharmaceuticals Tags: NPT Source Type: news
Nonprofit Organization to Award Funds for the Research of Pulmonary Hypertension
Team PHenomenal Hope (Team PH) seeks submissions for its PHenomenal Impact Fund for Global PH Research, marking the sixth consecutive year of funding innovative studies in pulmonary hypertension (PH) WHEATON, IL, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Non-profit organization Team PHenomenal... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 15, 2024 Category: Pharmaceuticals Tags: NPT AWD Source Type: news
AI boosts CTPA's ability to predict lung disease survival
The percentage of lung fibrosis quantified on CT pulmonary angiograms (CTPA) by an AI model is associated with increased risk of mortality -- and boosts clinicians' ability to predict the survival of lung disease patients, researchers have found.
The information is especially useful when used in combination with radiologic severity scoring -- compared with radiologic scoring alone -- and the study findings could help clinicians better care for their patients, wrote a team led by Krit Dwivedi, PhD, of the University of Sheffield in England. The results were published February 6 in Radiology.
"There is clinical need to bet...
Source: AuntMinnie.com Headlines - February 8, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Subspecialties Chest Radiology Source Type: news
Why I Stopped Being A “Good” Cancer Patient
“You are allergic to your oral chemotherapy,” explains my oncology team at a recent appointment. “We are going to try a newer drug,” I am on my fourth attempt to find an oral treatment suitable for both my body and my cancer, so that I can maintain a remission that took three years and a stem cell transplant to achieve. “We want to get ahead of it before it gets ahead of us.” In my headphones, Weezer achingly croons, “Say it ain’t so, your drug is a heartbreaker.”
[time-brightcove not-tgx=”true”]
Since being diagnosed with phase three chronic myeloid leu...
Source: TIME: Health - February 6, 2024 Category: Consumer Health News Authors: Walela Nehanda Tags: Uncategorized freelance Source Type: news
Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval
SHANGHAI, Jan. 2, 2024 -- (Healthcare Sales & Marketing Network) -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), recently announced that it has successfully obtained ... Devices, Regulatory, FDA, Reimbursement Pulnovo Medical, PADN Catheter, pulmonary arterial hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 2, 2024 Category: Pharmaceuticals Source Type: news
Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?
Liquidia Corp LQDA stock jumped after a win in a patent dispute with United Therapeutics Corporation UTHR revolving around U.S. Patent 10,716,793 (the ’793 patent). "We have considered United Therapeutics (UTC's) remaining arguments and find them unpersuasive," the three judge panel wrote in its…#liquidiacorp #unitedtherapeutics #utc #pah #tyvaso #fda #yutrepia #hatchwaxman #q3 #liquidia (Source: Reuters: Health)
Source: Reuters: Health - December 20, 2023 Category: Consumer Health News Source Type: news
Research into the burden of pulmonary hypertension published by Team PHenomenal Hope
Team PHenomenal Hope, a nonprofit advocacy organization, has published a research paper in Pulmonary Circulation titled "Patient perspectives on pulmonary hypertension in the United States: Burdens, expectations, and goals." The study illuminates the challenges faced by pulmonary... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 19, 2023 Category: Pharmaceuticals Tags: SVY NPT Source Type: news
Endobronchial ultrasound good for pulmonary hypertension screening
Endobronchial ultrasound may be used as a screening test for pulmonary hypertension in high-risk patients, a study published December 15 in JTCVS Techniques found. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 18, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Source Type: news
High-Altitude Mountain Trips Can Be Tolerated Despite Pulmonary Hypertension
(MedPage Today) -- Stable patients with pulmonary vascular disease (PVD) tolerated travel to high altitudes fairly well with frequent monitoring and supplemental oxygen therapy provided as necessary, a field study found.
Despite the perceived... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 12, 2023 Category: Cardiology Source Type: news
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with …
First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study) • FDA agreement that 6MWD will be the primary endpoint for both Phase 3 studies • Phase 3 program designed to satisfy FDA's request for subject drug exposure of 300 patients for 6 months, 100 patients for 1…#firstphase3 #fda #6mwd #phase3 #oral #uspto #hill #tenaxtherapeuticsinc #levosimendan #chrisgiordano (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2023 Category: Consumer Health News Source Type: news
